Dr. Mesa on Intended Patients With Myelofibrosis for Pacritinib

Ruben A. Mesa, MD
Published: Friday, Aug 14, 2015



Ruben A. Mesa, MD, deputy director, Mayo Clinic, discusses pacritinib for the treatment of patients with myelofibrosis and low platelet counts.

In the United States, there are approximately 20,000 patients with myelofibrosis, Mesa explains. An estimated one-third of these patients have thrombocytopenia. For patients with long-term disease, thrombocytopenia becomes more prevalent, he adds.

Overall, side effects associated with pacritinib were found to be manageable, as demonstrated in a recent study. Grade 1/2 gastrointestinal events, including diarrhea, nausea, and vomiting, were the most prevalent. Three enrolled patients discontinued treatment due to these adverse events, Mesa says.



Ruben A. Mesa, MD, deputy director, Mayo Clinic, discusses pacritinib for the treatment of patients with myelofibrosis and low platelet counts.

In the United States, there are approximately 20,000 patients with myelofibrosis, Mesa explains. An estimated one-third of these patients have thrombocytopenia. For patients with long-term disease, thrombocytopenia becomes more prevalent, he adds.

Overall, side effects associated with pacritinib were found to be manageable, as demonstrated in a recent study. Grade 1/2 gastrointestinal events, including diarrhea, nausea, and vomiting, were the most prevalent. Three enrolled patients discontinued treatment due to these adverse events, Mesa says.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Key Questions for the Use of Immunotherapy Throughout the Disease Continuum for NSCLC in an Era of Rapid DevelopmentSep 29, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing GlioblastomaSep 29, 20182.0
Publication Bottom Border
Border Publication
x